Canadian Alopecia Areata Foundation
Predictable for an unpredictable disease.
This press release was posted on Pfizer's website on December 4, 2023. A dual JAK3/TEC inhibitor, LITFULO™ (ritlecitinib) is approved for adults
We are pleased to share the “Attack from Within” alopecia patient video with you. This video follows Christal, Jen, Julia, and Sasha, as they share how alopecia affects their identity, their relationships, and their overall quality of life.
Article from BC Medical Journal: Navigating the emotional toll and financial burden of an unpredictable disease